Qiagen NV
NYSE:QGEN

Watchlist Manager
Qiagen NV Logo
Qiagen NV
NYSE:QGEN
Watchlist
Price: 43.24 USD -0.02%
Market Cap: 9.6B USD
Have any thoughts about
Qiagen NV?
Write Note

Net Margin
Qiagen NV

4.7%
Current
18%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.7%
=
Net Income
92.9m
/
Revenue
2B

Net Margin Across Competitors

Country NL
Market Cap 9.6B USD
Net Margin
5%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.2B USD
Net Margin
14%
Country US
Market Cap 170.9B USD
Net Margin
18%
Country KR
Market Cap 67.8T KRW
Net Margin
24%
Country CH
Market Cap 38.5B CHF
Net Margin
9%
Country US
Market Cap 38.6B USD
Net Margin
22%
Country US
Market Cap 36.5B USD
Net Margin
9%
Country US
Market Cap 26.7B USD
Net Margin
21%
Country US
Market Cap 23.2B USD
Net Margin
17%
Country US
Market Cap 23B USD
Net Margin
21%
No Stocks Found

Qiagen NV
Glance View

Market Cap
9.6B USD
Industry
Life Sciences Tools & Services

Qiagen NV is a leading global provider of sample and assay technologies that empower researchers and healthcare professionals in their quest for answers in genomics and molecular biology. Founded in 1984 and headquartered in Hilden, Germany, the company has established a formidable presence in the biotechnology sector, offering innovative solutions that facilitate the detection of diseases, genetic research, and drug development. Qiagen’s diverse portfolio spans from nucleic acid extraction kits to molecular diagnostic tests, catering to both academic research institutions and clinical settings. This extensive product range not only supports the growing demand for precision medicine but also aligns with global health trends emphasizing personalized treatments based on genetic insights. For investors, Qiagen presents an appealing opportunity as it operates in a lucrative market characterized by robust growth prospects. The company has consistently demonstrated its ability to adapt to changing healthcare landscapes, evidenced by its strategic focus on expanding offerings in molecular diagnostics and companion diagnostics, which underpin the future of targeted therapies. Additionally, Qiagen's commitment to innovation is underscored by significant investments in research and development, positioning it well to capitalize on advances in the rapidly evolving life sciences market. With a strong financial track record and a commitment to enhancing shareholder value through strategic partnerships and acquisitions, Qiagen is not just a participant in the biotech ecosystem; it is a leader steering the course for future advancements in health and research.

QGEN Intrinsic Value
41.23 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
4.7%
=
Net Income
92.9m
/
Revenue
2B
What is the Net Margin of Qiagen NV?

Based on Qiagen NV's most recent financial statements, the company has Net Margin of 4.7%.